Abstract | IMPORTANCE OF THE FIELD: AREAS COVERED IN THIS REVIEW: Preclinical studies with galiximab, an anti-CD80 primatized mAb, have been encouraging and have demonstrated antitumor activity against various B-cell lymphoma models, both as a single agent as well as in combination with rituximab. Data were reviewed from a PubMed literature search from 1975 to 2009 and also included a review of abstracts from published proceedings of annual meetings from the American Society of Hematology and International Conference of Malignant Lymphoma, Lugano. WHAT THE READER WILL GAIN: Readers will gain a better understanding of mechanisms of action (both documented and proposed) of galiximab. An update of currently available clinical data will be presented. TAKE HOME MESSAGE: Data from completed clinical trials are promising and galiximab is being studied in both upfront and relapsed settings with the potential of being incorporated into the future treatment of B-cell lymphoma.
|
Authors | Seema Bhat, Myron S Czuczman |
Journal | Expert opinion on biological therapy
(Expert Opin Biol Ther)
Vol. 10
Issue 3
Pg. 451-8
(Mar 2010)
ISSN: 1744-7682 [Electronic] England |
PMID | 20092425
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antibodies, Monoclonal
- Antineoplastic Agents
- B7-1 Antigen
- galiximab
|
Topics |
- Antibodies, Monoclonal
(therapeutic use)
- Antineoplastic Agents
(therapeutic use)
- B7-1 Antigen
(immunology)
- Humans
- Lymphoma, Non-Hodgkin
(drug therapy, immunology)
|